Home / Conditions / Cervical Disc Disease
Cervical Disc Disease: when insurers say no, reviewers often say yes
In 14 published external-review decisions involving cervical disc disease, independent physician reviewers overturned the insurer’s denial 28.6% of the time.
Published decisions
14
2001–2026
Overturned
28.6%
4 denials reversed
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 9 | 22.2% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 5 | 40% |
Typical time to a decision
20 days
Most land between 7 and 24 days
Handled as urgent
42.9%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for spine surgery on the neck.Findings: Two of the three physician reviewers found that the medical evidence supports the requested services in this clinical setting. There are significant benefits documented in the literature with respect to total disc replacement which results in improved general and disease-specific outcome measures and a lower rate of reoperation in the two-level disc replacement patients versus two-level anterior cervical discectomy and fusion control patients. With regards to the long-term results of cervical total disc replacement, there are significant benefits over the conventional multilevel anterior cervical discectomy and fusion.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for artificial disc replacement at C5-6 with Secure-C device. Findings: The physician reviewers found that currently, there are adequate data to support the safety and effectiveness of the Secure-C artificial disc in well selected patients. Studies noted that the Secure-C artificial disc is U.S. Food and Drug Administration (FDA) approved and shows superiority in overall success in single level use. For treating symptomatic cervical disc disease, cervical disc arthroplasty is superior to anterior cervical discectomy and fusion in terms of overall, neck disability index, and neurological success. Furthermore, cervical disc arthroplasty is superior in terms of patient satisfaction, range of motion at the operative level, and secondary surgical procedures rate.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: An enrollee has requested a Mobi-C two-level cervical total disc replacement procedure for treatment of her medical condition. Findings: Three physician reviewers found that upon review of the submitted documentation there is inadequate support for two-level cervical disc replacement (arthroplasty) in this case. There are alternative approaches that are likely to avoid potential complications of re-operation and would avoid the potential complications of double-level cervical total disc arthroplasty. In a study by researchers, pooled data from multiple sources were analyzed with an incidence of heterotopic ossification of 44.6% at 12 months after total disc arthroplasty and 58.2% at 24 months. The authors concluding that cervical total disc arthroplasty should be performed cautiously.
A 50-year-old male has requested Oxycontin 40mg tablet (#60), twice per day for treatment of his cervical disc disease. Findings: The physician reviewer found that based on review of the available records, the requested Oxycontin is not medically necessary for treatment of this patient’s medical condition. Such narcotics and at the doses prescribed to the patient is presently indicated for severe cancer pain in patients who are opioid tolerant and with a limited life expectancy. The patient has non-malignant chronic neck and wrist pain which will often worsen or recur as a result of opioid rebound. The current standard of care for chronic pain is treatment in a multidisciplinary practice to include physical therapy, massage therapy, cognitive behavioral therapy, and injections to help reduce pain (Fishman).
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for cervical disc disease was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.